ClinicalTrials.gg
Not yet recruitingNCT07476079Updated Apr 24, 2026

Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation

An interventional study of The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. and The subjective adjustment of an EAS based on thresholds from the pure tone audiogram. in Fitting Methods by EAS Patients, sponsored by Luzerner Kantonsspital. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Luzerner Kantonsspital · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms of speech intelligibility in quiet and noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.

Read the detailed description

As the indications for Cochlear Implant (CI) Surgery expand to also include hearing impaired patients with some residual hearing in the ipsilateral (to be implanted) ear, residual hearing preservation during the surgical intervention becomes even more important. It is also known from the literature that patients will benefit from having good residual acoustic hearing after CI-Implantation in terms of the sound quality. This is particularly so for speech comprehension in noise as well as for music perception with the CI.

Present-day clinical Sound Processor programming software provides Electric Acoustic Stimulation (EAS) to account for preserved residual hearing. For an optimized EAS fitting, it is postulated here that optimal conditions are achieved when the electric and acoustic stimulation do not overlap. To achieve this, the acoustic stimulation ought to be limited to only regions where there is still useful acoustic hearing, while the electric stimulation should also be restricted to regions where there is no longer significant useful acoustic hearing. In the Maestro clinical software, the threshold for significant useful acoustic hearing is set to 65 dB Hearing Level (HL). This then determines the cut-off frequency between the acoustic and electric stimulation regions.

The standard clinical Maestro software computes this cut-off based on a regular pure tone audiogram (PTA) which has been manually stored in the software. However, it is arguable that this does not always represent an accurate cut-off frequency required for optimal fitting because the audiogram thresholds themselves are subjective in nature and can often vary in a test-retest situation, depending on the attention and reaction times of the patient. It has been reported that the unaided thresholds do not play a significant role in the EAS fitting. In this respect, it may be more accurate and beneficial to use objective measures such as electrocochleography (ECochG) to determine the thresholds of the residual hearing.

The current family of Med-El Cochlear Implants are equipped with the capability to perform ECochG measurements using the implant's own intracochlear electrodes within the scala tympani. The measurements can also be conducted intraoperatively or postoperatively. This intracochlear ECochG feature of the implants therefore allows us to objectively determine the residual hearing thresholds.

The aim of this study is to discuss the advantages of objective fitting of the EAS compared to subjective fitting using a PTA with respect to speech intelligibility in quiet and in noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.

From the existing literature, it is not expected that there should be any significant gender effects. This also does not belong to the primary aims of this study and we will not be investigating this aspect.

02

Conditions studied

  • Fitting Methods by EAS Patients

Keywords

  • Cochlear Implant patients
  • Residual hearing in the low frequency range
  • EAS
  • fitting methods
  • electrocochleography
03

In context

Lead sponsor

Luzerner Kantonsspital is the lead sponsor of 61 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged between 18-85 years.
  2. Cochlear Implant (CI) candidates with measurable post-operative low-frequency residual hearing (125Hz \<65dB, 250Hz \<65dB, 500Hz \<65dB).
  3. Only patients with MED-EL EAS.
  4. Written must be obtained prior to study start.

Exclusion criteria

Exclusion Criteria:

  1. Patients with cognitive impairments who, as a result, lack the capacity to make decisions.
  2. Uncooperative patients regarding pure tone audiometry thresholds measurements.
  3. Morbus Menière or intracochlear/ vestibular schwannoma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Other
    Sequence A, subjective followed by objective fitting

    In this sequence, the EAS is fitted in the first three months (period 1) using the subjective fitting method based on the thresholds in the pure tone audiogram. This is followed by three months (period 2) fitting using the objective fitting method based on the thresholds from electrocochleography.

    Other: The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. · Other: The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.

  • Other
    Sequence B, objective followed by subjective fitting

    In this sequence, the EAS is fitted in the first three months (period 1) using the objective fitting method based on the thresholds from electrocochleography. This is followed by three months (period 2) fitting using the subjective fitting method based on the thresholds in the pure tone audiogram.

    Other: The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. · Other: The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.

Interventions

  • OtherThe objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study.

    Measured ECochG thresholds will be used in the initial EAS fitting in period 1 for sequence B. For sequence A, the ECochG-based EAS fitting (with up-to-date ECochG thresholds) will take place three months later at the beginning of period 2.

  • OtherThe subjective adjustment of an EAS based on thresholds from the pure tone audiogram.

    The control intervention is the subjective EAS fitting based on PTAs. This is provided to sequence A at the beginning of period 1 baseline and to sequence B at the beginning of period 2.

06

What researchers measure

Primary outcomes

  1. Speech Recognition Threshold (SRT50)

    The primary outcome measure is the Speech Recognition Threshold (SRT50) at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design). The SRT50 measures speech understanding in noise and is defined as the Signal-to-Noise Ratio (measured in dB SNR) which yields 50% speech understanding, as determined by the OLSA test.

    Time frame: Three months after EAS fitting

Secondary outcomes

  1. Subjective level of auditory benefit

    A secondary outcome measure is subjective level of auditory benefit at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design), as determined using the HISQUI-19 (Hearing Implant Sound Quality Index) questionnaire.

    Time frame: Three months after EAS fitting

  2. Subjectively preferred EAS fitting method

    The subjectively preferred EAS fitting method at the end of the study will be examined.

    Time frame: at the end of the study, six months after baseline

  3. Post-operative ECochG and PTA tresholds

    Post-operative ECochG and PTA thresholds at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design).

    Time frame: Three months after EAS fitting (either objective or subjective EAS fitting)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Schaefer S, Sahwan M, Metryka A, Kluk K, Bruce IA. The benefits of preserving residual hearing following cochlear implantation: a systematic review. Int J Audiol. 2021 Aug;60(8):561-577. doi: 10.1080/14992027.2020.1863484. Epub 2021 Jan 10. PubMed 33426931 ↗
  • Rajan G, Tavora-Vieira D, Baumgartner WD, Godey B, Muller J, O'Driscoll M, Skarzynski H, Skarzynski P, Usami SI, Adunka O, Agrawal S, Bruce I, De Bodt M, Caversaccio M, Pilsbury H, Gavilan J, Hagen R, Hagr A, Kameswaran M, Karltorp E, Kompis M, Kuzovkov V, Lassaletta L, Yongxin L, Lorens A, Manoj M, Martin J, Mertens G, Mlynski R, Parnes L, Pulibalathingal S, Radeloff A, Raine CH, Rajeswaran R, Schmutzhard J, Sprinzl G, Staecker H, Stephan K, Sugarova S, Zernotti M, Zorowka P, Van de Heyning P. Hearing preservation cochlear implantation in children: The HEARRING Group consensus and practice guide. Cochlear Implants Int. 2018 Jan;19(1):1-13. doi: 10.1080/14670100.2017.1379933. Epub 2017 Oct 26. PubMed 29073844 ↗
  • 15. Wagener KC, Kühnel V, Kollmeier B (1999b) Entwicklung und Evaluation eines Satztests für die deutsche Sprache III: Evaluation des Oldenburger Sprachtests. Z Audiol 38:86-95.
  • Wagener KC, Kühnel V, Kollmeier B (1999a) Entwicklung und Evaluation eines Satztests für die deutsche Sprache I: Design des Oldenburger Satztests. Z Audiol 38:4-15.
  • Hey M, Bohnke B, Mewes A, Munder P, Mauger SJ, Hocke T. Speech comprehension across multiple CI processor generations: Scene dependent signal processing. Laryngoscope Investig Otolaryngol. 2021 Jun 15;6(4):807-815. doi: 10.1002/lio2.564. eCollection 2021 Aug. PubMed 34401506 ↗
  • Gifford RH, Sunderhaus LW, Dawant BM, Labadie RF, Noble JH. Cochlear implant spectral bandwidth for optimizing electric and acoustic stimulation (EAS). Hear Res. 2022 Dec;426:108584. doi: 10.1016/j.heares.2022.108584. Epub 2022 Jul 28. PubMed 35985964 ↗
  • Gawliczek T, Mantokoudis G, Anschuetz L, Caversaccio MD, Weder S. Comparison of auditory brainstem response and electrocochleography to assess the coupling efficiency of active middle ear implants. Front Neurol. 2023 Sep 6;14:1231403. doi: 10.3389/fneur.2023.1231403. eCollection 2023. PubMed 37745650 ↗
  • Dillon MT, O'Connell BP, Canfarotta MW, Buss E, Hopfinger J. Effect of Place-Based Versus Default Mapping Procedures on Masked Speech Recognition: Simulations of Cochlear Implant Alone and Electric-Acoustic Stimulation. Am J Audiol. 2022 Jun 2;31(2):322-337. doi: 10.1044/2022_AJA-21-00123. Epub 2022 Apr 8. PubMed 35394798 ↗
  • Dalbert A, Weder S. [Application of extra- and intracochlear electrocochleography during and after cochlear implantation]. HNO. 2025 Jan;73(1):14-21. doi: 10.1007/s00106-024-01481-4. Epub 2024 May 18. German. PubMed 38761228 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for Nov 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
May 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476079
Lead sponsor
Luzerner Kantonsspital
Responsible party
Armina Kreuzer (Senior Audiologist, Luzerner Kantonsspital) — Principal investigator
First posted
Mar 17, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Armina Kreuzer, Dr.
Contact
armina.kreuzer@luks.ch
+41 205 50 59
Wai Kong Lai, Dr.
Contact
waikong.lai@luks.ch
Armina Kreuzer, Dr.
principal investigator · Luzerner Kantonsspital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion